NCT02318277

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 176 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.

Conditions

• Solid Tumors
• Head and Neck Cancer
• Lung Cancer
• UC (Urothelial Cancer)

Interventions

Type	Name	Description
DRUG	MEDI4736	MEDI4736 administered intravenously (IV) every two weeks (q2w)
DRUG	INCB024360	INCB024360: Oral daily dosing

Timeline

• Start date: 2015-01-05
• Primary completion: 2019-08-28
• Completion: 2020-10-16
• First posted: 2014-12-17
• Last updated: 2022-01-13
• Results posted: 2020-12-29

Locations

13 sites across 1 country: United States

Regulatory

• FDA-regulated drug study